Valneva SE
http://www.valneva.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Valneva SE
A Month After Lung Cancer Withdrawal, Takeda Gets Approval For New Colorectal Cancer Drug
The US FDA approved Fruzaqla (fruquintinib) for previously treated metastatic disease regardless of biomarker status. The drug, already approved in China, was de-risked when Takeda licensed it from HutchMed.
Durect Eyes Phase III In Alcoholic Hepatitis Despite Phase IIb Miss
Durect thinks its epigenetic modulator shows promise with data showing reduction in 90-day mortality despite missing the primary endpoint of mortality and liver transplant rate.
Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Emerging From Stealth Mode, Tesselate Bio Looks To Develop Next-Gen Synthetic Lethality Drugs
As investment and interest grows in synthetic lethality cancer treatments, Netherlands-headquartered Tesselate Bio hopes to expand horizons within the field by hitting the novel FANCM target and developing its own companion diagnostic.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- BliNK Biomedical SAS
- Crucell Sweden AB
- Iomai Corporation
- Intercell USA, Inc.
- Intercell AG, Vivalis
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice